非小细胞肺癌的免疫治疗：现在和未来（2026）

非小细胞肺癌的免疫治疗：现在和未来（2026）
主要免疫治疗策略
Major emerging immunotherapeutic strategies for NSCLC.

Click on image to zoom

A. Bispecific antibodies simultaneously target molecules such as PD-1 and VEGF, or PD-1 and CTLA-4, thereby inducing antibody-mediated cellular cytotoxicity. B. Novel immune checkpoint inhibitors target checkpoints beyond PD-(L)1 synergize with PD-(L)1 agents to enhance cytotoxic activity. C. Antigen-presenting cells internalize mRNA, translate it into tumour-associated and tumour-specific antigens, and thereby enhance their efficacy in antigen presentation. D. ADCs comprise monoclonal antibodies linked to cytotoxic payloads that specifically target surface antigens overexpressed on tumor cells, such as PD-L1, B7-H3, and Trop-2. Upon binding, the ADCs are internalized, delivering the cytotoxic agent directly into the cancer cells to induce cell death while minimizing systemic toxicity. E. Oncolytic viruses demonstrate tropism for malignant cells, selectively infecting and lysing tumour tissue, while concurrently eliciting a systemic antitumour immune response. F. Cell therapies encompass the procurement of immune cells from human donors, followed by ex vivo isolation, genetic engineering or phenotypic selection, and expansion, culminating in the infusion of these manipulated cells into patients to achieve therapeutic outcomes. NSCLC, Non-small cell lung cancer; VEGF, Vascular endothelial growth factor; CTLA-4, Cytotoxic T-lymphocyte-associated protein 4; ADCs, Antibody-drug conjugates; PD-1, Programmed cell death protein 1; PD-L1, Programmed cell death-ligand 1; TIM-3, T-cell immunoglobulin and mucin-domain containing 3; LAG-3, lymphocyte-activation gene 3; TIGIT, T-cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain; APCs, Antigen-presenting cells; TAA, Tumour-associated antigens; TSA, Tumour-specific antigens; DC, Dendritic cell; NK, Natural killer; mRNA, Messenger ribonucleic acid; B7-H3, B7 homolog 3; Trop-2, Trophoblast cell surface antigen 2


Zhou CY, Qi YF, Li HJ, Zhang C, Lin BX, Lin JT, Wu YL, Zheng MM, Zhong WZ. Current and future immunotherapies for NSCLC. J Hematol Oncol. 2026 Apr 29;19(1):28. doi: 10.1186/s13045-026-01791-w. PMID: 42057114; PMCID: PMC13130492.

Current and future immunotherapies for NSCLC - PMC